Trial Profile
Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms IVAS
- 20 Jul 2023 Planned End Date changed from 1 Jun 2019 to 1 Feb 2026.
- 20 Jul 2023 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2025.
- 17 Mar 2016 New trial record